01477.HK
Ocumension Therapeutics
HKSE · Healthcare · Biotechnology · CN
HKD 5.37
+1.23%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.5B | 804.4M | 417.3M | 246.4M | 159.0M |
| Cost of Revenue | 802.2M | 443.4M | 192.2M | 102.0M | 56.0M |
| Gross Profit | 669.7M | 360.9M | 225.1M | 144.4M | 102.9M |
| Operating Expenses | |||||
| R&D Expense | 162.7M | 75.1M | 113.9M | 123.8M | 184.3M |
| SG&A Expense | 910.2M | 446.0M | 271.0M | 279.0M | 373.8M |
| General & Admin Expense | 277.8M | 179.7M | 189.2M | 196.1M | 190.7M |
| Selling & Marketing Expense | 383.5M | 265.7M | 81.8M | 82.9M | 183.0M |
| Other Expenses | — | — | 144.2M | 143.7M | 683.0K |
| Total Operating Expenses | 1.1B | 521.1M | 529.1M | 546.5M | 558.8M |
| Cost and Expenses | 1.9B | 964.6M | 721.4M | 647.7M | 614.8M |
| Operating Income (EBIT) | (403.2M) | (160.2M) | (306.4M) | (402.1M) | (455.9M) |
| Non-Operating | |||||
| Interest Income | 14.3M | 6.2M | 22.2M | 21.9M | 28.2M |
| Interest Expense | 4.4M | 2.4M | 2.2M | 1.3M | 1.8M |
| Net Interest Income | 9.9M | 3.8M | 20.1M | 20.6M | 26.4M |
| Other Non-Op Income/Expense | 31.5M | 1.7M | 39.2M | 21.9M | 53.6M |
| Non-Operating Income (excl Interest) | — | — | (41.3M) | (24.0M) | (47.8M) |
| EBT (Pre-Tax Income) | (371.6M) | (158.5M) | (267.3M) | (379.5M) | (402.2M) |
| Income Tax Expense | 1.8M | 350.0K | 1.0M | 307.0K | 414.0K |
| Bottom Line | |||||
| Net Income | (373.4M) | (158.8M) | (268.3M) | (379.8M) | (402.6M) |
| Earnings from Cont. Ops | (373.4M) | (158.8M) | (268.3M) | (379.8M) | (402.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (373.4M) | (158.8M) | (268.3M) | (379.8M) | (402.6M) |
| Per Share | |||||
| Basic EPS | (HK$0.48) | (HK$0.20) | (HK$0.39) | (HK$0.59) | (HK$0.64) |
| Diluted EPS | (HK$0.48) | (HK$0.20) | (HK$0.39) | (HK$0.59) | (HK$0.64) |
| Revenue Per Share | HK$1.78 | HK$1.02 | HK$0.61 | HK$0.38 | HK$0.25 |
| Shares | |||||
| Basic Shares Outstanding | 825.1M | 791.2M | 687.9M | 649.2M | 632.5M |
| Diluted Shares Outstanding | 825.1M | 791.2M | 687.9M | 649.2M | 632.5M |
| Profitability Metrics | |||||
| EBITDA | (256.2M) | (30.0M) | (188.0M) | (320.6M) | (360.0M) |
| D&A | 146.9M | 130.3M | 77.1M | 57.5M | 40.5M |
| EBIT | (403.2M) | (160.2M) | (265.1M) | (378.2M) | (400.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026